Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa

ABSTRACT The role of novel β-lactam/β-lactamase inhibitor combinations in ceftazidime-nonsusceptible (CAZ-NS) and imipenem-nonsusceptible (IPM-NS) Pseudomonas aeruginosa has not been fully elucidated. This study evaluated the in vitro activity of novel β-lactam/β-lactamase inhibitor combinations aga...

Full description

Bibliographic Details
Published in:	Microbiology Spectrum
Main Authors:	Leilei Wang, Xuefei Zhang, Xun Zhou, Fan Yang, Qinglan Guo, Minggui Wang
Format:	Article
Language:	English
Published:	American Society for Microbiology 2023-06-01
Subjects:	Pseudomonas aeruginosa ceftazidime-avibactam imipenem-relebactam in vitro activity
Online Access:	https://journals.asm.org/doi/10.1128/spectrum.00932-23

Similar Items

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
by: Xueting Wang, et al.
Published: (2023-12-01)

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01)

AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility
by: Shawn Freed, Jr, et al.
Published: (2024-11-01)

Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa
by: Yulin Zhang, et al.
Published: (2022-04-01)

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
by: Isabel Machuca, et al.
Published: (2024-11-01)

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience
by: Cristiana Leanza, et al.
Published: (2024-07-01)

Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS
by: Ana Candela, et al.
Published: (2025-05-01)

Azithromycin represses evolution of ceftazidime/avibactam resistance by translational repression of rpoS in Pseudomonas aeruginosa
by: Congjuan Xu, et al.
Published: (2025-05-01)

IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES
by: Tuğrul Hoşbul, et al.
Published: (2022-07-01)

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
by: Baharak Babouee Flury, et al.
Published: (2023-04-01)

Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs
by: Ilias Karaiskos, et al.
Published: (2025-05-01)

Correction: Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
by: Baharak Babouee Flury, et al.
Published: (2025-07-01)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
by: James A. Karlowsky, et al.
Published: (2023-05-01)

Difficult-to-Treat <i>Pseudomonas aeruginosa</i> Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal
by: Pablo Vidal-Cortés, et al.
Published: (2025-02-01)

Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
by: Yiwei Zhu, et al.
Published: (2021-12-01)

Resistance Genes and Molecular Epidemiology in Ceftazidime-Avibactam-Resistant Pseudomonas aeruginosa Isolates
by: Neslihan ARICI, et al.
Published: (2023-10-01)

Ceftazidime–Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing <i>Klebsiella pneumoniae</i>
by: Li Ding, et al.
Published: (2022-04-01)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01)

Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017–2020
by: Pattarachai Kiratisin, et al.
Published: (2023-09-01)

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
by: María Fernanda Mojica, et al.
Published: (2023-04-01)

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
by: Chen J, et al.
Published: (2023-04-01)

Prevalence and molecular characteristics of ceftazidime-avibactam resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates
by: Yili Chen, et al.
Published: (2024-03-01)

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected in Turkey and the Middle East: ATLAS Global Surveillance Program 2018-2022
by: Meredith Hackel, et al.
Published: (2024-12-01)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
by: Dai Kurihara, et al.
Published: (2022-04-01)

Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in Pseudomonas aeruginosa clinical isolates
by: Bartosz J. Bartmanski, et al.
Published: (2025-07-01)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023-08-01)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
by: Soo Min Jang, et al.
Published: (2021-09-01)

Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study
by: Felice Valzano, et al.
Published: (2024-08-01)

Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam
by: Peiyao Jia, et al.
Published: (2025-09-01)

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam
by: Min Seo Kang, et al.
Published: (2024-06-01)

Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa
by: Yixin Kang, et al.
Published: (2023-06-01)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
by: Katherine Young, et al.
Published: (2019-07-01)

Treatment of UTIs Due to <i>Klebsiella pneumoniae</i> Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review
by: Caroline Chapelle, et al.
Published: (2021-11-01)

In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018
by: Pattarachai Kiratisin, et al.
Published: (2021-12-01)

Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR <i>Klebsiella pneumoniae</i> Sternal Infection Complicated by Bacteremia
by: Luca Pipitò, et al.
Published: (2025-10-01)

Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020
by: Mark G. Wise, et al.
Published: (2023-05-01)

Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan
by: Tsung-Ying Yang, et al.
Published: (2022-02-01)

In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021
by: Mark G. Wise, et al.
Published: (2023-12-01)